Methods. Between September 15-20 of 2019, 160 patients with gastrointestinal symptoms resulting from the ingestion of a common food, arrived at Fundación Valle del Lili. *Salmonella* spp were cultured from stool specimens of patients and 15 isolates were sent to the Genomic Unit of Agrosavia for whole-genome sequencing. *Salmonella* DNA was sequenced using an Illumina MiSeqX10 platform. Genome assembly was performed with standardized bioinformatics pipelines and in-silico serotyping with SISTR. Genomic comparisons included newly-sequenced isolates of *Salmonella* from a Colombian poultry farms as well as datasets from Patric(n=441) and EnterBase(n=54).

Results. The 15 outbreak isolates were identified by in silico serotyping as *S. infantis*, these isolates showed phenotypic sensitivity to all tested antibiotics except by tetracycline. Antimicrobial resistance plasmids IncFIBKpn3, IncX4 and the host-enviroment persistence plasmid pSL483 were only detected in 2 outbreak-related and 1 in poultry isolates. Out of a total of 511 high-quality sequences, ST32 was the most prevalent and were phylogenetically grouped into a single non-host specific clade. Outbreak isolates were included in a monophyletic group with some genomes from the US and Chile, suggesting that the parent strain could have originated in those countries.

Conclusion. The magnitude of the outbreak(288 informed-cases) evidenced the high-virulent potential of outbreak-isolates. Routine sequencing of S.enterica and availability of genomes in Colombia can improve outbreak detection and resolution in the future. The presence of plasmids, although with low frequency, suggests a risk of the appearance of resistant clones.

Disclosures. All Authors: No reported disclosures

1297. Azithromycin vs Beta Lactams in Acute Exacerbations of COPD
Pramodini Kale-Pradhan, Pharm.D.¹; Nour Baalbaki, Pharm.D.²; Bianca Aprilia, BS³; Christopher Giuliano, Pharm.D, MPH³; Carrie Hartner, Pharm.D.⁴; Leonard R. Johnson, MD⁵; Wayne State University/Ascension St. John Hospital, Detroit, Michigan; Ascension St John Hospital, Detroit, Michigan; Wayne State University, Detroit, Michigan; Wayne State University, Detroit, Michigan; Ascension St John Hospital, Detroit, Michigan

Session: P-73. Respiratory Infections - Bacterial Background. Bacterial infections cause approximately 50% of Acute Exacerbations of COPD (AECOPD). Current guidelines recommend a wide range of antibiotics, but evidence comparing agents is limited. The purpose of this study is to compare the effectiveness of azithromycin to beta lactams in the treatment of hospitalized patients with AECOPD.

Methods. A multicenter, retrospective, observational study of adult patients admitted with AECOPD who received at least two consecutive days of either a beta lactam or azithromycin were included. The primary endpoint was treatment failure (PF). Patients in the beta lactam group more likely to experience in-hospital mortality (P=0.002), require a new antibiotic, steroid therapy escalation, or readmission due to AECOPD within 30 days. Secondary endpoints included each individual component of the composite endpoint and length of stay.

Results. Of 11,395 patients screened, 595 met the inclusion criteria (428 were treated with azithromycin and 167 patients were treated with a beta lactam). The most common reason for exclusion was the receipt of both azithromycin and beta-lactam (P< 0.001), and were more likely to be readmitted within 30 days of discharge due to AECOPD (P=0.032). Length of stay was significantly shorter in the azithromycin group (P<0.001), and were more likely to be readmitted within 30 days of discharge due to AECOPD (P=0.032). Length of stay was significantly shorter in the azithromycin group compared to the beta lactam group. There were no statistically significant differences in the rates of adverse events among both groups.

Conclusion. Treatment failure rate and length of stay were significantly higher in the beta lactam group compared to the azithromycin group. However, there were no differences in the side effect profile among both groups. Further studies should be performed to confirm these findings.

Disclosures. All Authors: No reported disclosures

1298. Validation of Local Pseudomonas aeruginosa Risk Factors in Patients with Community-Onset Bacterial Pneumonia
Morgan Pizzuti, PharmD¹; Bailey Smith, PharmD Candidate²; Shannon Leighton, PharmD Candidate²; Chao Cui, PhD³; William Lindsey, MD⁴; P Brandon Bookstaver, Pharm D⁵; Joseph Kohn, PharmD, BCPS⁶; Majdi N. Al-hasan, MD⁷; Hana Winders, PharmD, BCIDP⁸; Julie Ann Justo, PharmD, MS, BCPS-AQ ID⁹; Prisma Health Richland - University of South Carolina, Columbia, South Carolina; University of South Carolina College of Pharmacy, Columbia, South Carolina; Prisma Health Midlands, Columbia, South Carolina; University of South Carolina, Columbia, SC

Session: P-73. Respiratory Infections - Bacterial Background. Clinical guidelines for community-acquired pneumonia (CAP) encourage validation of local risk factors for multidrug-resistant organisms. This study aimed to validate previously derived, local risk factors for *Pseudomonas aeruginosa* in patients with community-onset bacterial pneumonia at Prisma Health Midlands hospitals.

Methods. In this retrospective, observational cohort study, adult patients hospitalized with pneumonia MS-DRG codes from January 1, 2017 to March 31, 2020 were randomly screened. Enrolled subjects were admitted to 1 of 3 Prisma Health Midlands' hospitals with: diagnosis of pneumonia; receipt of inpatient antibiotics within 48 hours of symptom onset; receipt of over 48 hours of antibiotic therapy; and a cause-viable bacterial pathogen identified via respiratory or blood culture, urinary antigen, or respiratory multiplex PCR panel. Performance of the locally derived score was compared to the Drug Resistance in Pneumonia (DRIP) Score, IDSA 2019 CAP guideline risk factors, and healthcare-associated pneumonia (HCAP) risk factors. Endpoints included sensitivity, specificity, positive and negative predictive value, overall accuracy, and over- and under-treatment rates. Overall accuracy was defined as a case in which the gram-negative antibiotic coverage recommended by the scoring schema would have been appropriate for the identified organism, i.e. neither overtreatment (over broad-spectrum) nor undertreatment (inadequate spectrum).

Results. Of 713 patients screened, 36 patients met criteria and were enrolled. The most common bacterial pathogens identified were *Pseudomonas aeruginosa* (n = 10, 27.8%) and *Streptococcus pneumoniae* (n = 10, 27.8%). Performance characteristics for each scoring schema are summarized in Table 1.

Table 1. Performance characteristics of risk scores predicting for *Pseudomonas aeruginosa* community-onset bacterial pneumonia.

| Table 1: Performance characteristics of risk scores predicting for *Pseudomonas aeruginosa* community-onset bacterial pneumonia. |
|---|
| **Score** | **Sensitivity** | **Specificity** | **PPV** | **NPV** | **Accuracy** |
| CAP=Community acquired pneumonia | 100% | 100% | 100% | 100% | 100% |
| DRIP=Drug Resistance in Pneumonia | 82% | 98% | 91% | 88% | 90% |
| IDSA=Infectious Diseases Society of America | 88% | 94% | 91% | 91% | 93% |

Conclusions. Compared to DRIP or IDSA 2019 CAP risk scores, the local risk score performed well at ruling out resistant gram-negatives given its higher specificity and lower overtreatment rate; yet, it did not perform as well as ruling in resistant gram-negatives given a lower sensitivity and undertreatment rate. All scores performed better than HCAP risk factor. Data from this study will be utilized to further refine the local risk score algorithm.

Disclosures. P Brandon Bookstaver, Pharm D, ALK Abello, Inc. (Grant/Research Support, Advisor or Review Panel member)/Biomerieux (Speaker's Bureau)/Kedrion Biopharma (Grant/Research Support, Advisor or Review Panel member)/Hana Winders, PharmD, BCIDP, biomerieux (Speaker/Research Support)/Julie Ann Justo, PharmD, MS, BCPS-AQ ID, bioMerieux (Speaker's Bureau)/Meerk & Co. (Advisor or Review Panel member)/Therapeutic Research Center (Speaker)/Vaxart (Shareholder)

1299. Epidemiology of Invasive Pneumococcal Disease (IPD) in the United States 2011-2019
Ryan Gierke, MPH²; Monica A. Farley, MD³; William Schaffner, MD³; Ann Thomas, MD, MPH³; Art Reingold, MD⁴; Lee Harrison, MD⁴; Corinne Hoffmann, MPH⁵; Kari Burrall, MPH⁶; Susan Petit, MPH⁷; Meghan Barnes, MSPH⁸; Salima Torres, PhD, MPH⁹; Bernard Beall, PhD⁹; Tamara Pilishvili, PhD⁹; Centers for Disease Control and Prevention, Atlanta, Georgia; Emory University, Atlanta, Georgia; Vanderbilt University Medical Center, Nashville, Tennessee; Oregon Public Health Division, Portland, Oregon; University of California, Berkeley, Berkeley, CA; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; Minnesota Department of Health, St. Paul, Minnesota; New York State Department of Health, Buffalo, New York; Connecticut Department of Public Health, Hartford, Connecticut; Colorado Department of Public Health and Environment, Denver, Colorado; New Mexico Department of Health, Santa Fe, New Mexico; Centers for Disease Control and Prevention, Atlanta, GA, USA, Atlanta, Georgia

Session: P-73. Respiratory Infections - Bacterial Background. Thirteen-valent pneumococcal conjugate vaccine (PCV13) was recommended for U.S. children aged ≤ 5 years in February 2010 and recommended in series with 23-valent pneumococcal polysaccharide vaccine (PPV23) for adults aged ≥ 65 years in 2014. PCV13 has led to dramatic reductions in invasive pneumococcal disease (IPD) burden. New, higher valency PCVs (PCV15, PCV20) are expected to be licensed for adults in late 2021. We examined remaining PCV13-type IPD among children and adults and assessed IPD burden potentially preventable through PCV15 and PCV20 site.

Methods. IPD cases (isolation of pneumococcus from sterile sites) were identified through CDC's Active Bacterial Core surveillance during 1998–2018. Isolates were serotyped by Quelling or whole genome sequencing. Incidence rates (cases/100,000) were calculated using U.S. Census Bureau population denominators.

Results. After introduction of PCV13 in children, in 2013–2014, PCV13-type IPD declined 89% (from 15 to 2 cases/100,000) in children age ≤ 5 years and 67% (from 19 to 7 cases/100,000) in adults age ≥ 65 years. During 2014–2019, rates of PCV13-type IPD in children and adults remained stable. In 2018–2019, among children age ≤ 5 years, serotypes 3, 19F, 19A, and 6C accounted for most of the remaining